Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
about
Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma UndergoiDerived neutrophil/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancerThe Promises of Quantitative Proteomics in Precision MedicineRole of solute carrier transporters in pancreatic cancer: a review.Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis.Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under GemcitabineGenomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
P2860
Q34234101-051F050F-287D-46D0-B9D2-0D15A705B09BQ34507964-C1CAD356-CDAF-477D-97C3-C04481588F5EQ35086475-92670D6F-BF4E-4F98-98A9-7AF78F561AEBQ36342657-ACE2B946-6AE2-456D-8111-CDCE625E5FF7Q36822149-6ECA426A-3344-4E49-8454-9B2F0CCBE7BAQ36825610-B7E6DDC7-DE1A-4A09-B646-8E31A0AD9846Q37647264-D3A443FD-9F6E-49A4-9383-06F69A8B8745Q38236028-58BE56A6-F8C8-43E7-B2E3-F3168D05B7ABQ38946461-6420C47D-0B63-44CD-82ED-1239B6118351Q39283216-FC26C934-449B-4A18-BE15-7B6559720B34Q41487497-C236A6E7-3738-4009-AB38-F3771ACFDB62Q45220444-8BEB0C2D-C5C3-4B6B-A3CD-1C60CC0610A1
P2860
Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Human equilibrative nucleoside ...... unresectable pancreatic cancer
@ast
Human equilibrative nucleoside ...... unresectable pancreatic cancer
@en
type
label
Human equilibrative nucleoside ...... unresectable pancreatic cancer
@ast
Human equilibrative nucleoside ...... unresectable pancreatic cancer
@en
prefLabel
Human equilibrative nucleoside ...... unresectable pancreatic cancer
@ast
Human equilibrative nucleoside ...... unresectable pancreatic cancer
@en
P2093
P2860
P356
P1476
Human equilibrative nucleoside ...... unresectable pancreatic cancer
@en
P2093
A Takasawa
H Kawakami
M Kuwatani
N Sakamoto
S Kawahata
P2860
P2888
P304
P356
10.1038/BJC.2013.108
P407
P577
2013-03-14T00:00:00Z